Covalent Drug-Polymer Copolymers for Uniform Coating Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug release systems for medical devices face challenges such as impurities triggering adverse biological responses, phase separation compromising mechanical properties, and instability of biologically active agents, leading to non-uniform distribution and reduced efficacy.
Innovation Solution
Development of compounds with biologically active agents linked via oligomeric segments, forming a stable coating that ensures uniform distribution and controlled release of drugs, maintaining mechanical properties and stability, using structures like Bio-Link-Bio-R, where Bio units are anti-inflammatory agents and Link is an oligomeric organic, organosilicon, or organosulfone segment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biologically active agents are mixed with polymer platform in solvent system, then drug delivery is achieved, but phase separation occurs compromising mechanical properties
Solution Approach 1:
The patent combines the biologically active agent and polymer platform into a single copolymer structure where the drug is incorporated into the polymer backbone or side chains. This merging eliminates phase separation by ensuring molecular-level mixing, while the copolymer maintains mechanical integrity through its unified polymeric structure.
Solution Approach 2:
The invention creates a composite copolymer material where hydrophilic drug-containing segments and hydrophobic polymer segments are covalently bonded. This composite structure at the molecular level prevents macroscopic phase separation while maintaining the mechanical properties needed for coating applications.
2Duration of action of stationary object
If biologically active agents are incorporated into polymer, then extended release is achieved, but impurities trigger adverse biological responses
Solution Approach 1:
The patent modifies the chemical structure of the biologically active agent by incorporating it into the polymer chain, changing its physical state from free drug to polymer-bound drug. This parameter change allows controlled release through polymer degradation or dissolution, extending duration while the pure copolymer structure eliminates impurity-related adverse responses.
3Reliability
If biologically active agents are mixed with polymer, then drug release is achieved, but uniform distribution is compromised
Solution Approach 1:
By merging the drug molecule with the polymer chain through covalent bonding during copolymerization, the patent achieves uniform distribution at the molecular level. Each polymer chain contains drug units distributed throughout its structure, ensuring homogeneous drug placement without the aggregation problems of simple mixing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable and uniform drug release profile, maintaining mechanical properties and ensuring localized therapeutic concentrations, with reduced biological activity, enhancing the compatibility and effectiveness of the drug delivery system.
Implementation Method 1
compounds with biologically active agents linked via oligomeric segments
Implementation Method 2
The biologically active agent is then released by particle dissolution or diffusion
Implementation Method 3
it may be released as the polymer enzymatically degrades or disintegrates in the body
Data Source
Figure 1-A
Figure 1-B
Figure 2A~2D
AI summary
The invention relates to compounds that include biologically active agents (e.g., compounds according to any of formulas (I) and (I-A) that can be used for effective drug release, e.g., as coatings for medical devices. Use of these compounds in the coating of surfaces can allow for long-term drug release as well as imparting uniform coatings with little phase separation compared to, e.g., the parent biologically active agent.